Trial Profile
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Lapatinib (GW572016) in Combination With Paclitaxel Versus Paclitaxel Plus Placebo in Subjects With ErbB2 Amplified Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms CHINA
- Sponsors GlaxoSmithKline; GSK; Novare Pharmaceuticals
- 18 Jan 2022 Status changed from active, no longer recruiting to completed.
- 18 May 2021 Planned End Date changed from 15 May 2021 to 31 Dec 2021.
- 02 Mar 2021 Planned End Date changed from 31 Dec 2021 to 15 May 2021.